Norelgestromin/ethinylestradiol
| Combination of | |
|---|---|
| Norelgestromin | Progestogen |
| Ethinylestradiol | Estrogen |
| Clinical data | |
| Trade names | Ortho Evra, Xulane, Evra, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a602006 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Transdermal (patch) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C41H53NO4 |
| Molar mass | 623.878 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Norelgestromin/ethinylestradiol, sold under the brand name Ortho Evra among others, is a contraceptive patch containing the progestin norelgestromin and the estrogen ethinylestradiol.[4][6][7]
The most common side effects include headache, nausea (feeling sick), breast tenderness, and irregular uterine bleeding.[6][4]
Norelgestromin/ethinylestradiol is a transdermal patch (a patch that delivers a medicine across the skin).[6] For the first three weeks of the menstrual cycle a new patch should be applied every week, followed by a fourth week, which is patch-free.[6] The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms.[6] Transdermal patches must always be applied on the same day of the week to the buttock, abdomen (belly), upper arm or upper back.[6] The same area of skin should not be used for two consecutive patches.[6] Norelgestromin/ethinylestradiol may work less well in women weighing 198 pounds (90 kg) or more.[6]
Norelgestromin/ethinylestradiol was approved for medical use in the United States in November 2001, and in the European Union in August 2002.[8][6] It is available as a generic medication.[4][9]
Medical uses
[edit]In the United States norelgestromin/ethinylestradiol is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m2 for whom a transdermal delivery system is an appropriate method of contraception.[4]
In the European Union, norelgestromin/ethinylestradiol is indicated for use as female contraception.[6]
See also
[edit]- Combined injectable contraceptive
- Contraceptive vaginal ring
- Oral contraceptive formulations
- List of combined sex-hormonal preparations
References
[edit]- ^ "Evra Product information". Health Canada. 21 June 2018. Retrieved 17 February 2020.
- ^ "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Archived from the original on 24 October 2020. Retrieved 4 July 2020.
- ^ "Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) Initial U.S. Approval: 2001". DailyMed. 12 July 2018. Retrieved 4 July 2020.
- ^ a b c d e "Xulane- norelgestromin and ethinyl estradiol patch". DailyMed. 7 April 2020. Retrieved 4 July 2020.
- ^ "Ortho Evra: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 4 July 2020.
- ^ a b c d e f g h i j "Evra EPAR". European Medicines Agency (EMA). 5 August 2008. Retrieved 4 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Graziottin A (2006). "A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch". Treatments in Endocrinology. 5 (6): 359–65. doi:10.2165/00024677-200605060-00004. PMID 17107221. S2CID 21033630.
- ^ "Drug Approval Package: Ortho EVRA (Norelgestromin/Ethinyl Estradiol Transdermal System NDA #21-180". U.S. Food and Drug Administration (FDA). Retrieved 4 July 2020.
- ^ "Xulane (Norelgestromin and Ethinyl Estradiol Transdermal System), 150 mcg/35 mcg per day" (PDF). Abbreviated New Drug Application. U.S. Food and Drug Administration. 16 April 2014.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |